Ada Andino
Family · Elizabeth, NJNPI 1609582741
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 102 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 19.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,071 and has fallen 59.0% since, to $439 in 2025.
Across 102 payments — averaging $20.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$392
- Novo Nordisk$318
- GSK$275
- Eisai Inc.$159
- Lilly USA, LLC$146
- AbbVie$142
- plus $617 from 15 others
What the payments were for
- Speaking & faculty fees$141%
- Food & beverage$2,03599%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 20 | $392 |
| Novo Nordisk | 14 | $318 |
| GSK | 10 | $275 |
| Eisai Inc. | 3 | $159 |
| Lilly USA, LLC | 9 | $146 |
| AbbVie | 9 | $142 |
| Bayer | 7 | $119 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $116 |
| Merck | 4 | $64 |
| Amgen | 3 | $47 |
| Boehringer Ingelheim | 3 | $45 |
| Otsuka America Pharmaceutical, Inc. | 2 | $36 |
| Exact Sciences | 1 | $33 |
| Johnson & Johnson | 2 | $33 |
| Kowa Pharmaceuticals America, Inc. | 2 | $29 |
| Corcept Therapeutics | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Tonix Medicines, Inc. | 1 | $16 |
| Scilex Pharmaceuticals Inc. | 1 | $16 |
| Medicure Pharma Inc. | 1 | $14 |
| Novartis | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,050 in reported general payments places this provider in the 85th percentile of 2,692 family providers in New Jersey.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 296 | $320,514 |
| OzempicSemaglutide | 127 | $147,168 |
| ProliaDenosumab | 82 | $143,867 |
| LinzessLinaclotide | 153 | $137,802 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 131 | $106,041 |
| VascepaIcosapent Ethyl | 189 | $102,728 |
| JardianceEmpagliflozin | 64 | $83,291 |
| RybelsusSemaglutide | 61 | $77,556 |
| TrulicityDulaglutide | 71 | $76,392 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 84 | $66,644 |
| EliquisApixaban | 59 | $54,844 |
| MyrbetriqMirabegron | 84 | $54,503 |
| MounjaroTirzepatide | 46 | $48,873 |
| XareltoRivaroxaban | 38 | $38,633 |
| JanumetSitagliptin Phos/Metformin Hcl | 33 | $34,688 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $392 | $393,135405 claims |
| Novo NordiskOzempic, Rybelsus | $318 | $224,724188 claims |
| AbbVieLinzess, Creon | $142 | $167,541173 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy, Synjardy Xr, Trijardy Xr | $45 | $166,692153 claims |
| AmgenProlia | $47 | $143,86782 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $275 | $126,197175 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $146 | $125,265117 claims |
| MerckJanumet, Belsomra, Janumet Xr, Januvia | $64 | $80,720111 claims |
| Johnson & JohnsonXarelto | $33 | $38,63338 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $17 | $6,55011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,692 family providers in New Jersey.
Other family in Elizabeth
- Jennifer DemaioMorristown$412K
- Kara TrlicaCranbury$186K
- Nicole BauerParamus$161K
- China BattistaWall Township$142K
- Nancy EisenbergerVoorhees$82K
- Jennifer AbitabiloGlen Ridge$54K
- Megan FiloramoMorristown$53K
- Shawn DenningToms River$29K
- Kimberly ClementeEatontown$25K
- Toni Michelle SeibertColumbus$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.